 |
|
Naltrexone Treatment for Alcohol Dependency
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The study by Dr Garbutt and colleagues1 demonstrates that the use of injectable naltrexone reduces the number of heavy drinking days in alcohol-dependent individuals. An important limitation in these results is that despite the long duration of the trial, the number of heavy drinking days per month did not progressively decrease over time, suggesting that longer treatment would be of no additional benefit. This is not surprising since craving, which is the strongest predictor of subsequent drinking and relapse,2 has never been reported to be completely eliminated by naltrexone. Reduction of heavy drinking days has been previously established in randomized trials with the oral administration of the craving-reducing agents naltrexone,3 topiramate,4 and low-dose baclofen,5 and in an open-label trial of acamprosate.6
In validated animal models of craving for ethanol,7 only one of these medications, baclofen, which is a GABA(b) receptor agonist, has been shown at high dose . . . [Full Text of this Article]
Olivier Ameisen, MD
oameisen@noos.fr
Paris, France
RELATED ARTICLES
Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
, , , , , , , , and
JAMA. ;293():1617-1625.
FULL TEXT
Naltrexone Treatment for Alcohol Dependency--Reply
, , , , , , , and
JAMA. ;294():900-900.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
SUPPRESSION OF SYMPTOMS OF ALCOHOL DEPENDENCE AND CRAVING USING HIGH-DOSE BACLOFEN
BUCKNAM
Alcohol Alcohol 2007;42:158-160.
ABSTRACT
| FULL TEXT
|
